semaglutide study weight loss Long-term effects of in obesity without diabetes in the SELECT trial Tirzepatide shows 47% greater weight

A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively

3.5 Semaglutide intervention and fecal microbiota transplantation improved the dysbiosis of gut microbiota in obese mice, increasing the relative abundance of beneficial bacteria, and affecting the levels of short-chain fatty acids The species accumulation curve and dilution curve indicated that the sample size and sequencing depth were sufficient (Supplementary Figure S3A)

Call us or request an appointment online today.

Accessed 18 February 2021 Leung E, Wongrakpanich S, Munshi MN (2018) Diabetes management in the elderly